These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 29446691)

  • 1. Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany.
    Wachter R; Viriato D; Klebs S; Grunow SS; Schindler M; Engelhard J; Proenca CC; Calado F; Schlienger R; Dworak M; Balas B; Bruce Wirta S
    Postgrad Med; 2018 Apr; 130(3):308-316. PubMed ID: 29446691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany.
    Wachter R; Fonseca AF; Balas B; Kap E; Engelhard J; Schlienger R; Klebs S; Wirta SB; Kostev K
    Eur J Heart Fail; 2019 May; 21(5):588-597. PubMed ID: 30972918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world analysis of integration of sacubitril/valsartan into clinical practice in Saudi Arabia.
    Badreldin HA; Korayem GB; Alenazy BA; Aljohani MH; Alshaya OA; Al Sulaiman K; Alabdelmuhsin L; Alenazi H; Almutairi DM; Alanazi F; Alobathani SK; Alqannam GM; Almadani O; Aljuhani O; Hafiz A; Aljowaie G; Basha E; Alqahtani T; Alhussein M
    Medicine (Baltimore); 2023 Dec; 102(51):e36699. PubMed ID: 38134075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure.
    Mentz RJ; Xu H; O'Brien EC; Thomas L; Alexy T; Gupta B; Vilaro J; Lala A; DeVore AD; Dhingra R; Briasoulis A; Simon MA; Stehlik J; Rodgers JE; Dunlay SM; Abshire M; Wells QS; Barringhaus KG; Eckman PM; Lowes BD; Espinoza J; Blanco R; Shen X; Duffy CI; Hernandez AF
    Am Heart J; 2020 Dec; 230():35-43. PubMed ID: 32980364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure.
    Albert NM; Swindle JP; Buysman EK; Chang C
    J Am Heart Assoc; 2019 May; 8(9):e011089. PubMed ID: 31023122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart failure signs and symptoms, hospital referrals, and prescription patterns in patients receiving sacubitril/valsartan in primary care and cardiologist settings in Germany.
    Wachter R; Klebs S; Balas B; Kap E; Engelhard J; Schlienger R; Bruce Wirta S; Fonseca AF
    ESC Heart Fail; 2020 Oct; 7(5):2318-2330. PubMed ID: 33121216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of sacubitril/valsartan in patients with heart failure in primary care in Germany: the AURORA-HF noninterventional study.
    Zeymer U; Groves R; Hupfer S
    Herz; 2024 Oct; 49(5):385-392. PubMed ID: 38656397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan.
    Selvaraj S; Claggett BL; Böhm M; Anker SD; Vaduganathan M; Zannad F; Pieske B; Lam CSP; Anand IS; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2020 Apr; 75(14):1644-1656. PubMed ID: 32192799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of sacubitril/valsartan versus angiotensin receptor blockers in patients with heart failure with preserved ejection fraction: A real-world study.
    Riaz M; Smith SM; Dietrich EA; Winchester DE; Guo J; Park H
    Am J Health Syst Pharm; 2024 Jul; 81(14):599-607. PubMed ID: 38427969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
    Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W
    J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event.
    Mentz RJ; Ward JH; Hernandez AF; Lepage S; Morrow DA; Sarwat S; Sharma K; Solomon SD; Starling RC; Velazquez EJ; Williamson K; Zieroth S; Braunwald E
    J Card Fail; 2023 Jun; 29(6):922-930. PubMed ID: 36796671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into implementation of sacubitril/valsartan into clinical practice.
    Martens P; Beliën H; Dupont M; Mullens W
    ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
    DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
    JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of early sacubitril/valsartan patients and considerations for studies in electronic health record data.
    Gagne JJ; Tsacogianis T; Bruce Wirta S; Rogers JR; Calado F; Chang CL; Turner SJ; Schlienger RG; Balas B; Abdurrob A; Najafzadeh M; Wang SV
    J Comp Eff Res; 2018 Nov; 7(11):1073-1082. PubMed ID: 30156128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of functional class, biochemical and echocardiographic parameters and clinical outcomes after sacubitril/valsartan initiation in daily practice.
    Morillas-Climent H; Seller-Moya J; Vicedo-López Á; Galcerá-Jornet E; Alania-Torres E; Rodríguez-Pichardo Y; Larumbe-Rodríguez A; Valle-Muñoz A
    J Comp Eff Res; 2019 Jul; 8(9):685-697. PubMed ID: 31290687
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
    Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
    Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
    Myhre PL; Vaduganathan M; Claggett B; Packer M; Desai AS; Rouleau JL; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2019 Mar; 73(11):1264-1272. PubMed ID: 30846338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System.
    Han J; Chung F; Nguyen QL; Mody FV; Jackevicius CA
    Pharmacotherapy; 2019 Nov; 39(11):1053-1059. PubMed ID: 31498903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
    Okumura N; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
    Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.